Skip to content
AI IntelligenceMay 4, 2026Primary Market
Article

EnteroBiotix · £19M · Series Unknown

EnteroBiotix has secured £19 million in funding to support a clinical trial for microbiome-based therapies targeting irritable bowel syndrome. The company is based in Glasgow.

Data Cube AI EditorialSource: Unknown
01

Source Brief

EnteroBiotix has secured £19 million in funding to support a clinical trial for microbiome-based therapies targeting irritable bowel syndrome. The company is based in Glasgow.